Antiviral drug

Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 7, 2021
Medical specialties, Health sciences, Health, Healthcare-associated infections, Hepatitis, Steatohepatitis, Non-alcoholic fatty liver disease, Liver disease, Virus, Coronavirus, Biopharmaceutical, Antiviral drug

A recording of the webcast presentation will be available within 24 hours of the presentation and will be available for 30 days through the Investors section of the Aligos website.

Key Points: 
  • A recording of the webcast presentation will be available within 24 hours of the presentation and will be available for 30 days through the Investors section of the Aligos website.
  • https://investor.aligos.com
    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
  • Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH).
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Therapeutic Solutions International Reports QuadraMune™ Administration Enhances T Cytotoxic Responses in Mouse Model of Adaptive Immunity

Retrieved on: 
Tuesday, January 5, 2021
Branches of biology, Medical specialties, Biology, Immunology, T cells, Immune system, Immunotherapy, Antiviral drug, Cytotoxic T cell, Cell-mediated immunity, T helper cell

T cytotoxic cells are a component of the immune system which selectively kills virally infected cells.

Key Points: 
  • T cytotoxic cells are a component of the immune system which selectively kills virally infected cells.
  • "Last week we reported data that QuadraMune increases Th1 cell activity, which orchestrates antiviral immunity.
  • The T cytotoxic cell being the actual effector cells of adaptive antiviral immunity," said Dr. James Veltmeyer, Chief Medical Officer of the Company.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

Retrieved on: 
Tuesday, January 5, 2021
Health, Medicine, Antiviral drug, Biocides, Virus, Influenza

BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces management will present at the H.C. Wainwright Virtual BioConnect Conference being held January 11-14, 2021.

Key Points: 
  • BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces management will present at the H.C. Wainwright Virtual BioConnect Conference being held January 11-14, 2021.
  • The presentation can be accessed on the IR Calendar section of the Cocrystal website beginning on January 11, 2021 at 6:00 a.m. Eastern time.
  • We are pleased with our progress in 2020 in advancing our pipeline of novel antiviral compounds, said Gary Wilcox, Ph.D., Chairman and Chief Executive Officer of Cocrystal.
  • Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.

Worldwide Industry for Uveitis Treatment to 2025 - by Treatment Type, Disease Type, Cause, Distribution Channel and Region

Retrieved on: 
Thursday, December 31, 2020
Medical specialties, Clinical medicine, Medicine, Uveitis, Medication, Immunosuppressive drug, Antibiotic, Antiviral drug, Corticosteroid

The global uveitis treatment market grew at a CAGR of around 6% during 2014-2019.

Key Points: 
  • The global uveitis treatment market grew at a CAGR of around 6% during 2014-2019.
  • Some of the commonly used uveitis treatment methods include topical, systemic and local corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, analgesics and antivirals and antifungal medicines.
  • Looking forward, the publisher expects the global uveitis treatment market to continue its moderate growth during the next five years.
  • What is the structure of the global uveitis treatment market and who are the key players?

World Market Outlook for Anti-microbial, Anti-viral, and Anti-fungal Nanocoatings to 2030

Retrieved on: 
Thursday, December 31, 2020
Biocides, Health, Articles, Infectious diseases, Epidemiology, Antimicrobial, Mold, Antiviral drug, Virus

DUBLIN, Dec. 31, 2020 /PRNewswire/ -- The "The Global Market for Anti-microbial, Anti-viral, and Anti-fungal Nanocoatings 2010-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 31, 2020 /PRNewswire/ -- The "The Global Market for Anti-microbial, Anti-viral, and Anti-fungal Nanocoatings 2010-2030" report has been added to ResearchAndMarkets.com's offering.
  • Nanocoatings can demonstrate up to 99.9998% effectiveness against bacteria, formaldehyde, mold and viruses, and are up to 1000 times more efficient than previous technologies available on the market.
  • Nanocoatings companies have partnering with global manufacturers and cities to develop anti-viral facemasks, hazard suits and easily applied surface coatings.
  • Anti-microbial, anti-viral and anti-fungal nanocoatings applications include, but are not limited to:
    Fabrics and clothing like face masks;
    Hotels and other public spaces;

Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™ Rapid Detection Test of SARS-CoV-2 Viral Antigen

Retrieved on: 
Wednesday, December 30, 2020
Life sciences, Health sciences, Articles, Zoonoses, Covi, Pharmaceutical industry, Biotechnology, Biopharmaceutical, Antiviral drug, Coronavirus disease, Virus

In testing conducted to date, COVI-STIX has provided results within 15 minutes, with positive detection as quickly as two minutes for patient samples with high viral load.

Key Points: 
  • In testing conducted to date, COVI-STIX has provided results within 15 minutes, with positive detection as quickly as two minutes for patient samples with high viral load.
  • An independent study conducted by researchers of the Facultad de Medicina, UNAM demonstrated high sensitivity and specificity in Mexico patients with COVID-19 symptoms.
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers.
  • Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-MSC and COVI-DROPS; and diagnostic test solutions, including COVI-TRACK, COVI-STIX and COVI-TRACE.

Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

Retrieved on: 
Wednesday, December 30, 2020
Life sciences, Medical specialties, Health, Infectious causes of cancer, Healthcare-associated infections, Viral diseases, Vaccine-preventable diseases, Hepatitis, Antiviral drug, Liver disease, Biopharmaceutical, CHB

GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a novel peptide-based immunotherapeutic under development for treatment of chronic hepatitis B (CHB).

Key Points: 
  • GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a novel peptide-based immunotherapeutic under development for treatment of chronic hepatitis B (CHB).
  • There is no cure for CHB, and currently available antiviral medications only control the disease and require life-long treatment.
  • These treatments represent a significant economic burden for chronic hepatitis B patients, due to the life-long commitment to medication and monitoring.
  • Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease.

SYNLawn® Indiana Offering Antiviral Solution to Combat Covid-19

Retrieved on: 
Tuesday, December 29, 2020
Articles, Health, Antiviral drug, Biocides, Artificial turf, Virus, Playground, Indianapolis

INDIANAPOLIS, Dec. 29, 2020 /PRNewswire/ -- If you are one of the many individuals concerned about the Covid-19 pandemic, SYNLawn Indiana has announced that they are offering an antiviral solution called ProGienics to eliminate the virus off synthetic grass and hard surfaces.

Key Points: 
  • INDIANAPOLIS, Dec. 29, 2020 /PRNewswire/ -- If you are one of the many individuals concerned about the Covid-19 pandemic, SYNLawn Indiana has announced that they are offering an antiviral solution called ProGienics to eliminate the virus off synthetic grass and hard surfaces.
  • Households and businesses with indoor putting greens, safety flooring, playgrounds and more, can purchase this product directly from SYNLawn Indiana.
  • With the new year quickly approaching, SYNLawn Indiana is excited to announce the unveiling of their new website.
  • To learn more about ProGienics and how SYNLawn Indiana can make the community brighter and safer during this challenging time, you can visit www.indianaartificiallawns.com .

Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen

Retrieved on: 
Tuesday, December 22, 2020
Covi, Antiviral drug

In testing conducted to date, COVI-STIX has provided results within 15 minutes, with positive detection as quickly as two minutes for patient samples with high viral load.

Key Points: 
  • In testing conducted to date, COVI-STIX has provided results within 15 minutes, with positive detection as quickly as two minutes for patient samples with high viral load.
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers.
  • Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-MSC and COVI-DROPS; and diagnostic test solutions, including COVI-TRACK, COVI-STIX and COVI-TRACE.
  • RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.

Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses

Retrieved on: 
Tuesday, December 22, 2020
Health sciences, Health, Medicine, Animal virology, Coronavirus, Virus, Severe acute respiratory syndrome coronavirus, Antiviral drug

That agreement provides Cocrystal with an exclusive, royalty-bearing license to develop and commercialize therapeutic, diagnostic and prophylactic products against coronaviruses, caliciviruses and picornaviruses based on antivirals discovered by KSURF.

Key Points: 
  • That agreement provides Cocrystal with an exclusive, royalty-bearing license to develop and commercialize therapeutic, diagnostic and prophylactic products against coronaviruses, caliciviruses and picornaviruses based on antivirals discovered by KSURF.
  • Following preclinical studies by Cocrystal, we have selected CDI-45205 as having promising attributes in combatting a range of coronaviruses, including SARS-CoV-2, said Sam Lee, Ph.D., President of Cocrystal.
  • Our further testing allowed us to identify a promising candidate molecule among these compounds for our lead development program.
  • Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.